Company Profile
BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products.
Development Pipeline
BTG’s internal development pipeline comprises six clinical stage development programmes and ten partnered products in clinical stage development.
Marketed and Other Revenue Generating Products
BTG earns revenues from product sales and from royalties on products marketed by licensees/partners. For the Year ended 31 March 2010, the major contributors to revenues were:
|
Product |
Use/Indication |
2009/10 Gross
Revenues (£m) |
|
BeneFIX® |
Haemophilia B |
26.6 |
|
CroFab™ |
Crotalid anti-venom |
24.2 |
|
Two-Part Hip Cup |
Hip replacement |
10.8 |
|
DigiFab™ |
Digoxin antidote |
5.4 |
|
MRC Humanisation IP |
Various antibodies |
5.1 |
|
Campath® |
Chronic lymphocytic leukaemia |
4.5 |
|
Voraxaze™* |
Delayed MTX elimination |
3.4 |
| Other |
Various |
8.4 |
*Voraxaze™ is an investigational new drug that is available in the US under a Treatment Protocol and elsewhere outside the US on a named patient basis. Voraxaze™ is not approved in any country, and safety and efficacy have not been established for any use.
Analyst Research
Sam Fazeli/Tracey Butcher, Piper Jaffray
Gary Waanders, Nomura Code
Robin Davison, Edison Investment Research
Elizabeth Klein, Singer Capital Markets
Paul Cuddon, KBC Peel Hunt
Stefan Hamill, Noble Investments
Keith Redpath, FinnCap
Philippa Gardner, Jefferies
Chris Redhead, Ambrian Capital
Vadim Alexandre, Daniel Stewart